Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Zwiebel

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
The effect on drug development of the National Cancer Institute's Cancer Therapy Evaluation ProgramJames Zwiebel
JAMA Oncology|March 10, 2017
Planning Adjuvant Trials When Regimens Effective for Patients With Advanced Disease Don't Work in the Adjuvant Setting-Paradigms LostBhupinder Mann, James Zwiebel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2014
Improving the protocol implementation process: the National Cancer Institute's responseJeffrey S Abrams, Margaret Mooney, James Zwiebel, et al.
The Oncologist|May 22, 2010
Development of rational drug combinations with investigational targeted agentsAdam Clark, Matthew Ellis, Charles Erlichman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studiesDella Makower, Alla Rozenblit, Howard Kaufman, et al.
Seminars in Radiation Oncology|September 14, 2016
Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic CollaborationNaoko Takebe, Mansoor M Ahmed, Bhadrasain Vikram, et al.
Investigational New Drugs|March 4, 2005
Phase II trial of fenretinide in advanced renal carcinomaUlka Vaishampayan, Lance K Heilbrun, Ralph E Parchment, et al.
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|March 28, 2003
Clinical applications of p53-directed gene therapyScott Wadler, Della Makower, Bo Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2006
Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301Helen X Chen, Margaret Mooney, Matthew Boron, et al.
Cancer|August 28, 2009
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 ConsortiumDeborah Bradley, Dana Rathkopf, Rodney Dunn, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
The effect on drug development of the National Cancer Institute's Cancer Therapy Evaluation ProgramJames Zwiebel
JAMA Oncology|March 10, 2017
Planning Adjuvant Trials When Regimens Effective for Patients With Advanced Disease Don't Work in the Adjuvant Setting-Paradigms LostBhupinder Mann, James Zwiebel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2014
Improving the protocol implementation process: the National Cancer Institute's responseJeffrey S Abrams, Margaret Mooney, James Zwiebel, et al.
The Oncologist|May 22, 2010
Development of rational drug combinations with investigational targeted agentsAdam Clark, Matthew Ellis, Charles Erlichman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studiesDella Makower, Alla Rozenblit, Howard Kaufman, et al.
Seminars in Radiation Oncology|September 14, 2016
Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic CollaborationNaoko Takebe, Mansoor M Ahmed, Bhadrasain Vikram, et al.
Investigational New Drugs|March 4, 2005
Phase II trial of fenretinide in advanced renal carcinomaUlka Vaishampayan, Lance K Heilbrun, Ralph E Parchment, et al.
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|March 28, 2003
Clinical applications of p53-directed gene therapyScott Wadler, Della Makower, Bo Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2006
Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301Helen X Chen, Margaret Mooney, Matthew Boron, et al.
Cancer|August 28, 2009
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 ConsortiumDeborah Bradley, Dana Rathkopf, Rodney Dunn, et al.
Pageof 4